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Abstract
Background: A variety of mint [Mentha spicata] has been bred which over-expresses Rosmarinic acid (RA) by 
approximately 20-fold. RA has demonstrated significant anti-inflammatory activity in vitro and in small rodents; thus it 
was hypothesized that this plant would demonstrate significant anti-inflammatory activity in vitro. The objectives of 
this study were: a) to develop an in vitro extraction procedure which mimics digestion and hepatic metabolism, b) to 
compare anti-inflammatory properties of High-Rosmarinic-Acid Mentha spicata (HRAM) with wild-type control M. 
spicata (CM), and c) to quantify the relative contributions of RA and three of its hepatic metabolites [ferulic acid (FA), 
caffeic acid (CA), coumaric acid (CO)] to anti-inflammatory activity of HRAM.
Methods: HRAM and CM were incubated in simulated gastric and intestinal fluid, liver microsomes (from male rat) and 
NADPH. Concentrations of RA, CA, CO, and FA in simulated digest of HRAM (HRAMsim) and CM (CMsim) were determined 
(HPLC) and compared with concentrations in aqueous extracts of HRAM and CM. Cartilage explants (porcine) were 
cultured with LPS (0 or 3 μg/mL) and test article [HRAMsim (0, 8, 40, 80, 240, or 400 μg/mL), or CMsim (0, 1, 5 or 10 mg/
mL), or RA (0.640 μg/mL), or CA (0.384 μg/mL), or CO (0.057 μg/mL) or FA (0.038 μg/mL)] for 96 h. Media samples were 
analyzed for prostaglandin E2 (PGE2), interleukin 1β (IL-1), glycosaminoglycan (GAG), nitric oxide (NO) and cell viability 
(differential live-dead cell staining).
Results: RA concentration of HRAMsim and CMsim was 49.3 and 0.4 μg/mL, respectively. CA, FA and CO were identified in 
HRAMsim but not in aqueous extract of HRAM. HRAMsim (≥ 8 μg/mL) inhibited LPS-induced PGE2 and NO; HRAMsim (≥ 80 
μg/mL) inhibited LPS-induced GAG release. RA inhibited LPS-induced GAG release. No anti-inflammatory or 
chondroprotective effects of RA metabolites on cartilage explants were identified.
Conclusions: Our biological extraction procedure produces a substance which is similar in composition to post-
hepatic products. HRAMsim is an effective inhibitor of LPS-induced inflammation in cartilage explants, and effects are 
primarily independent of RA. Further research is needed to identify bioactive phytochemical(s) in HRAMsim.
Background
Rosmarinic acid (RA; C18H16O8) is a polyphenolic car-
boxylic acid found in many herbal plants including rose-
mary (Rosmarinus officinalis), oregano (Origanum
vulgare) and mint (commonly Mentha spicata or Mentha
× piperita). RA has widely reported biological activities in
mammals and mammalian cells including antioxidant [1],
anti-inflammatory [2], antitumor [3,4], immunomodula-
tory [5], antiviral [4] and antibacterial [6]. There is con-
siderable scientific support for an anti-inflammatory role
for RA. It has shown significant inhibitory effects on
inflammation induced by lipopolysaccharide (LPS) in
bone-marrow-derived dendritic cells [7], primarily by
inhibiting chemokine recruitment of macrophages via the
Mitogen Activated Protein Kinase (MAPK) cell signalling
pathway. RA has also shown inhibitory effect on LPS-
induced production of nitric oxide (NO) and inducible
nitric oxide synthase (iNOS) in macrophages, an action
mediated in part by an ability of RA to prevent phospho-
rylation of an inhibitor protein on NF-κB (Iκ-Bα). This
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prevents binding of this nuclear transcription factor to
DNA encoding a series of inflammatory proteins, thus
reducing their biological expression [8].
Mint (Mentha spicata) is a common natural source for
RA. Like pure RA, mint oil also inhibits the inflammatory
consequences of LPS, including inhibition of interleukin-
1 (IL-1), prostaglandin E2 (PGE2), leukotriene B4 (LTB4)
production by LPS-stimulated human monocytes [9]. As
these biological actions are considered to be related to the
RA content of the plant, considerable effort has been
invested in developing strategies to upregulate biosynthe-
sis of RA by genetically modified (GMO) plant tissues
[10,11]. These efforts have successfully resulted in RA
production of up to 45 mg/g plant tissue (dry weight;
DW). However , widespread commercialization of these
technologies has lagged, due in varying degrees to techni-
cal difficulty, low capacity for production of biomass, and
complex regulatory environment for GMO products.
Thus, there remains a commercial opportunity for agro-
nomic selection of plants with naturally robust biosyn-
thesis of RA for the nutraceutical and biotechnology
markets.
Recently, selective breeding of Mentha spicata clones
has generated plants which naturally over-produce RA,
resulting in tissue concentrations of up to 122 mg/g DW
[12,13] - more than double the content of high-RA-pro-
ducing control clones and three times higher than other
GMO plants [10]. The processed High-Rosmarinic-Acid
M. spicata resulting from these experiments (HRAM) has
shown marked antioxidant activity in vitro [12,13] and
may be an ideal candidate for nutritional intervention for
inflammatory diseases.
We have previously described an in vitro cartilage
explant model to assess the cartilage-sparing and anti-
inflammatory properties of dietary nutraceuticals [14,15].
While this model effectively accounts for the effects of
gastric digestion and ultrafiltration of molecules, it does
not provide any measure of biotransformation/bioactiva-
tion which occurs in the liver in vivo. This is a significant
limitation when assessing the bioactivity of herbal prod-
ucts in vitro because secondary plant metabolites are, in
many cases, extensively modified by cytochrome P450
enzymes [16,17]. Thus, observed bioactivity of secondary
plant metabolites (such as rosmarinic acid) in vitro may
not accurately reflect their bioactivity in vivo.
The objectives of the current study were 1) to produce a
biological extract of HRAM by adapting an artificial
digestion procedure for the purpose of simulating hepatic
metabolism of putative anti-inflammatory botanicals, 2)
to compare the anti-inflammatory and/or chondropro-
tective properties of HRAM and a wild-type M. spicata
(CM) in LPS-stimulated cartilage explants, and 3) to
determine whether anti-inflammatory activity of HRAM
can be attributed to its RA content, or the primary
hepatic metabolites of RA.
We hypothesized that 1) a biological extraction proce-
dure which simulates digestion and hepatic metabolism
of HRAM (HRAMsim) would produce a substance con-
taining RA and its primary hepatic metabolites including
caffeic acid (CA), m-coumaric acid (CO), and ferulic acid
(FA) [18]; 2) HRAMsim would modulate the inflammation
and degradation associated with exposing cartilage
explants to LPS to a greater magnitude than CM; and 3)
anti-inflammatory activity of HRAMsim would be attrib-
uted, at least in part, to RA and/or hepatic metabolites of
RA.
Methods
All materials and reagents were purchased from Sigma
Aldrich (Mississauga ON Canada) unless otherwise
stated.
Plant material
Spearmint seed (Mentha spicata L.) was sourced from
Stokes Seeds Ltd., St. Catharines ON, Canada. Seed was
germinated at the University of Guelph (Dept of Plant
Agriculture) and planted in a research plot at the Univer-
sity of Guelph. Plant material was harvested at vegetative
maturity and air dried at 35°C to a dry matter content of
~89%.
Simulated digestion and hepatic metabolism
HRAM and CM (0.85 g) were individually added to ali-
quots of simulated gastric fluid and simulated intestinal
fluid as previously described [14,19,20]. Resulting mix-
tures were filtered (0.22 μm) and pH was adjusted to 7.4.
In order to simulate hepatic metabolism of RA, liver
microsomes from rat (male) (Sigma Aldrich, Mississauga
ON Canada) were added to a final concentration of 0.03
mg/mL [21] followed by NADPH (100 μg in 0.01 M
NaOH) [21]. Solutions were incubated for a further 30
min at 37°C, 7% CO2[21], followed by centrifugation
(2500 rpm for 20 min). Supernatants were filtered (0.22
μm), placed into 50 kDa ultrafiltration centrifuge units
(Amicon Ultra; Millipore, Mississauga ON), and centri-
fuged at 3000 rpm for 25 min at room temperature. The
resulting 50 kDa fractions were refrigerated (4°C) until
use. A 'blank' simulated digest was made using the identi-
cal methodology but without including any HRAM or
CM.
Phytochemical analysis of simulated digests
Metabolic breakdown products of RA were quantified by
HPLC. Briefly, a Gilson 506C HPLC system equipped
with Unipoint 2.1 software (Gilson, Middleton, WI, USA)
equipped with a 234 auto-injector, dual pumps, column
heater, and 118 UV/Vis detector was used for metabolitePearson et al. BMC Complementary and Alternative Medicine 2010, 10:19
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detection. Digests were injected onto a Supelco C18 Dis-
covery column (250 × 4.6 mm, 35°C, detector sensitivity
0.015) and eluted with a mixture of 0.1% phosphoric acid
(A) and acetonitrile (B). Separation was achieved at a flow
rate of 1 mL/min using a linear gradient of 83%-77% A
over 45 min, then 77-64% A over 2 min, 64-44% A over 10
min, 44-0% over 2 min, maintaining for 4 min, then
returning to starting conditions and maintain for 5 min
for a total run time of 75 min. Standards of RA (25 μg/
mL), CO (5 μg/mL), FA (1 μg/mL), and CA (1 μg/mL)
were injected as internal standards.
Cartilage explants
Cartilage tissue was obtained from a commercial, feder-
ally inspected meat packing facility. Cartilage explants (4
mm diameter; 11-17 mg/explant) were excised from the
articulating surface of the intercarpal joint of healthy pigs
using a sterile dermal biopsy tool [14]. Explants were
placed 2 per well into a 24-well tissue culture plate and
maintained in culture for a total of 96 h. Media (1000 μL)
was removed from each well every 24 h. For the first 48 h
of culture (prior to exposure to LPS), media samples were
discarded. During the final 48 h (immediately prior to
and during stimulation with LPS) samples were collected
into sterile microcentrifuge tubes containing 10 μg indo-
methacin in DMSO and immediately frozen (-20°C) until
analysis.
Treatments
Tissue from a total of 17 animals were used for these
experiments. For the first 24 h of culture, tissue culture
media [TCM: Dubelco's Modified Eagle Medium plus
ascorbic acid, antibiotics (10 mL/L containing 10,000
units penicillin; 10 mg streptomycin/mL), dexametha-
sone, amphotericin B, amino acids, manganese sulphate,
lactalbumin hydrolysate, sodium selenite, NaHCO3, and
fetal bovine serum (10%)] [19] contained no HRAMsim or
LPS. From 24 - 120 h of culture, explants were exposed to
treatments as follows:
HRAMsim [0 (ie. 'blank'), 8, 40, 80 μg/mL] (n = 6)
HRAMsim (0, 80, 240, 400 μg/mL) (n = 5)
Assuming a total body water content of 42 L [31], these
amounts are approximately equivalent to a daily dose of
0, 0.3, 1.7, 3.3, 10.1 and 16.8 g (respectively) of HRAM for
an average 78 kg person. Each treatment was evaluated in
the presence or absence of LPS (3 μg/mL).
For experiments in which individual bioactivity of RA,
CA, CO, and FA was determined, stock solutions of each
compound were prepared using 35% ethanol in distilled
water. Aliquots of stock solutions were diluted 1:999 with
distilled water. Aliquots of diluted stock solutions were
suspended in 'blank' simulated digest and filtered (0.22
μm) before use.
CM (0, 1.0, 5.0, 10.0 mg/mL) (n = 6 - same animals as
RA and CO treatments)
RA (0.640 μg/mL), CA (0.384 μg/mL) (n = 6 - same
animals as CM and CO treatments)
CO (0.057 μg/mL), or FA (0.038 μg/mL) (n = 6 - same
animals as CM and RA treatments)
As the RA concentration of HRAMsim was approxi-
mately 125 times higher than that of CMsim, the concen-
tration of CMsim used in this experiment was 125 times
those of HRAMsim in order to standardize the amount of
RA to which explants were exposed. Concentration of RA
and its metabolites used in this experiment was equiva-
lent to the concentration of each compound in a HRAM-
sim dose of 80 μg/mL (see Table 1)
For the final 48 h, all explants were exposed to an
inflammatory stimulus (LPS; 0 or 3 μg/mL) in order to
upregulate production of inflammatory eicosanoids and
catabolic enzymes.
Table 1: Concentrations of metabolites identified in aqueous extract and simulated digest of HRAM and CM.
Compound HRAM [μg/mL] Control Mint [μg/mL]
Aqueous/Ethanolic 
extract^
Simulated digest Aqueous/Ethanolic 
extract^
Simulated digest
Rosmarinic acid [RA] 720.0 49.3 16.1 0.4
Caffeic acid [CA] nd* 33.0 2.1 2.2
Ferulic acid [FA] nd* 3.4 2.5 2.6
Coumaric acid [CO] nd* 4.6 2.2 2.2
^Aqueous/ethanolic extracts are based on 5 mg of leaf tissue in 3 mL of water/ethanol [50:50 v/v], microwave extraction for 2.2 minutes at 
240 watts. * not detectedPearson et al. BMC Complementary and Alternative Medicine 2010, 10:19
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Sample analysis
All assays plates were read on an ELX 800 Universal
Microplate Reader (Biotech Instruments Inc., Winooski,
VT) unless otherwise indicated. PGE2, GAG, and NO
concentrations were determined as follows:
PGE2
TCM samples were analyzed for PGE2 using a commer-
cially available kit (R&D Systems). Plates were read at
absorbance of 450 nm. A best-fit 3rd order polynomial
standard curve was developed for each plate (R2 ≥ 0.99),
and these equations were used to calculate PGE2 concen-
trations for samples from each plate.
GAG
TCM GAG concentration was determined using a 1,9-
Dimethyl Methylene Blue (1,9-DMB) spectrophotometric
assay [19]. Samples were added to 96-well plates at 50%
dilution, and serially diluted 1:2 up to a final dilution of
1:64. Guanidine hydrochloride (275 mg/mL) was added
to each well followed immediately by addition of 150 μL
DMB reagent. Absorbance was measured at 530 nm.
S a m p l e  a b s o r b a n c e  w a s  c o m p a r e d  t o  t h a t  o f  a  b o v i n e
chondroitin sulfate standard (Sigma, Oakville ON). A
best-fit linear standard curve was developed for each
plate (R2 ≥ 0.99), and these equations used to calculate
GAG concentrations for samples on each plate.
NO2
Nitrite (NO2-), a stable oxidation product of NO, was
analyzed by the Griess reaction [19]. Undiluted TCM
samples were added to 96 well plates. Sulfanilamide (0.01
g/mL) and N-(1)-Napthylethylene diamine hydrochloride
(1 mg/mL) dissolved in phosphoric acid (0.085 g/L) was
added to all wells, and absorbance was read within 5 min
at 530 nm. Sample absorbance was compared to a sodium
nitrite standard. A best-fit linear standard curve was
developed for each plate (R2 ≥ 0.99), and these equations
were used to calculate nitrite concentrations for samples
from each plate.
Cell viability
Viability of cells within cartilage explants [all treatments
excluding HRAM (240 and 400 μg/mL) was determined
using a Calcein-AM (C-AM)/Ethidium homodimer-1
(EthD-1) cytotoxicity assay kit (Molecular Probes) modi-
fied for use in cartilage explants [19]. C-AM and EthD-1
were mixed in sterile distilled water at concentrations of 4
and 8 μM, respectively. Explants were placed one per well
into a sterile 96-well microtitre plate and incubated in
200 μL of the C-AM/EthD-1 solution for 40 min at room
temperature. The microplate reader (Victor 3 1420
Microplate Reader, Perkin Elmer, Woodbridge ON) was
set to scan each well, beginning at the bottom, using 10
horizontal steps at each of 3 vertical displacements set 0.1
mm apart. C-AM and EthD-1 fluorescence in explants
were obtained with using excitation/emission filters of
485/530 nm and 530/685 nm, respectively.
IL-1
TCM from explants treated with HRAM (0, 8, 40, 80 μg/
mL) were analyzed for IL-1 using a commercially avail-
able kit (R&D Systems). Plates were read at absorbance of
450 nm. A best-fit 3rd order polynomial standard curve
was developed for each plate (R2 ≥ 0.99), and these equa-
tions were used to calculate IL-1 concentrations for sam-
ples from each plate.
Statistical analysis
Data from the final 48 h of culture (ie. from immediately
prior to and during exposure to LPS) are presented as
mean ± SE. Time '0 h' is the baseline sample after the first
48 h of culture before addition of LPS. Each animal repre-
sents a single observation (ie. experimental unit). To
compare effects of treatments over time, PGE2, GAG, NO
and IL-1 data were analyzed using 2-way ANOVA (Sig-
maStat, Version 11) with respect to treatment and time.
To determine changes in dependent variables over time
within individual treatments, one-way ANOVA was used
to detect changes in dependent variables over time within
treatments. Viability data were analyzed using a paired
difference t-test comparing each treatment with control.
When a significant F-ratio was obtained, the Holm-Sidak
post-hoc test was used to detect significantly different
means. Significance was accepted when p < 0.05.
Results
HPLC analysis
Chromatogram of HRAM aqueous extract and HRAM
simulated digest is provided in Figure 1A and 1B respec-
tively. Concentrations of RA and its primary hepatic
metabolites identified in HRAMsim, CMsim, and aqueous
extracts of HRAM and CM are reported in Table 1.
PGE2
LPS significantly increased PGE2 in explants which were
not conditioned with HRAMsim (Figure 2A). Compared
with controls, HRAMsim induced a strong, dose-depen-
dent inhibition of PGE2 at all doses tested. LPS produced
a significant increase in PGE2 in explants conditioned
with the lowest dose of HRAMsim (8 μg/mL), but PGE2
production by these explants was still significantly lower
than in controls. LPS did not increase PGE2 production
by explants conditioned with all other doses of HRAMsim.
In unstimulated explants, HRAMsim (8, 40, 80, 240 and
400 μg/mL) significantly reduced PGE2 at all time points
compared with unstimulated controls (Figure 2B).Pearson et al. BMC Complementary and Alternative Medicine 2010, 10:19
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Figure 1 HPLC chromatogram of aqueous extract [A] and biological extract B] of High-Rosmarinic Acid Mint [HRAM]. [A] The major peak rep-
resents rosmarinic acid [RA] at a concentration of 130 ug/mL. [B] Retention times of compounds of interest: Caffeic acid = 6.00 min; Ferulic acid = 10.52 
min; m-Coumaric acid = 14.10 min; Rosmarinic acid = 20.50 min.
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There was no significant effect of any dose of CMsim,
RA or any RA metabolite on PGE2 production in LPS-
stimulated or unstimulated explants (Additional file 1).
NO
LPS significantly (p < 0.001) increased nitric oxide pro-
duction compared with unstimulated control explants
(Figure 3A). All concentrations of HRAMsim significantly
inhibited NO response to LPS, with the exception of 400
μg/mL, which non-significantly (p = 0.1) reduced NO.
In unstimulated explants, only the highest doses of
HRAMsim  (240 and 400 μg/mL) significantly reduced
nitric oxide production (Figure 3B).
There was no significant effect of CMsim, RA or any RA
metabolites on NO production by LPS-stimulated or
unstimulated explants (Additional file 1).
GAG
LPS significantly (p < 0.001) increased media GAG con-
centrations compared with unstimulated control explants
(Figure 4A and 4B). LPS-induced GAG release was signif-
icantly inhibited by HRAMsim (80, 240 and 400 μg/mL),
but not by the two lowest doses (Figure 4A).
HRAMsim  (40 μg/mL) significantly (p = 0.007)
increased GAG release by unstimulated explants (Figure
4B).
Figure 2 Figure - Prostaglandin E2 [PGE2] production by cartilage explants stimulated with LPS [3 or 0 μg/mL; Panels A and B, respectively]. 
Explants were conditioned with HRAMsim [0, 8, 40, 80, 240 or 400 μg/mL] for 96 h, and were stimulated with LPS for the final 48 h. Data shown are for 
the final 48 hours only. * represents significant effect of LPS; -- represents treatments significantly different from controls.
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Figure 3 Nitric Oxide [NO] production by cartilage explants stimulated with LPS [3 or 0 μg/mL; Panels A and B, respectively]. Explants were 
conditioned with HRAMsim [0, 8, 40, 80, 240 or 400 μg/mL] for 96 h, and were stimulated with LPS for the final 48 h. Data shown are for the final 48 
hours only. * represents significant effect of LPS; -- represents treatments significantly different from controls.
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There was no significant effect of CMsim or any RA
metabolites in LPS-stimulated explants. RA significantly
reduced GAG release in LPS-stimulated explants at 24 h
compared with stimulated control explants (Additional
file 1).
Cell viability
LPS did not significantly alter the ratio of live-to-dead
cells within the cartilage explants (Figure 5).
There was no significant effect of HRAMsim (Figure 5)
or CMsim (Additional file 1) on cell viability at any dose
either in the presence or absence of LPS.
Viability of unstimulated explants conditioned with CO
was significantly reduced (Additional file 1). There were
no other significant effects of RA or its metabolites on
viability in stimulated or unstimulated explants.
IL-1
LPS significantly increased media IL-1 compared with
unstimulated controls (p = 0.01) (Figure 6A and 6B).
Peak LPS-induced IL-1 concentration from explants
conditioned with HRAMsim (80 μg/mL) (6.23 ± 2.0 pg/
mL) was approximately 50% that of peak IL-1 in stimu-
lated controls (12.9 ± 2.3 pg/mL), but this difference was
not significant (p = 0.1) (Figure 6A).
There was no significant effect of HRAMsim condition-
ing on IL-1 concentration in media from cartilage
explants that were not exposed to LPS (Figure 6B).
Discussion
The current paper describes a simple and effective
method for simulating digestion and hepatic metabolism
of anti-inflammatory compounds intended for oral
administration. We have used this methodology to pre-
pare a biological extract of an herbal plant, which was
subsequently demonstrated to have marked inhibitory
activity on mediators of cartilage inflammation and deg-
radation.
The biological extraction procedure reported herein is
intended to improve upon simulated digestion proce-
dures we have reported previously [14,15] by incorporat-
ing the effects of liver metabolism. It is known that many
secondary plant metabolites undergo extensive hepatic
bioactivation and/or biotransformation [22], and these
metabolic end-products often produce biological effects
that differ markedly from those of the parent compound
[23]. While RA was identified in the aqueous extract of
HRAM, no hepatic metabolites were identified in this
Figure 5 Viability of cells within cartilage explants stimulated 
with LPS [0 or 3 μg/mL]. Explants were conditioned with HRAMsim [0, 
8, 40, or 80 μg/mL] for 96 h, and were stimulated with LPS [0 or 3 μg/
mL] for the final 48 h. Data shown are from the end of the 48 hour stim-
ulation period.
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final 48 hours only. * represents significant effect of LPS; -- represents treatments significantly different from controls.
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preparation. Identification of hepatic metabolites in the
biological extract provided evidence that incubating
HRAM in the presence of liver microsomes and NADPH
resulted in metabolism of RA to selected hepatic prod-
ucts, including FA, CA, and CO.
The total amount of RA and its associated hepatic
metabolites recovered from the microsomal digest of
HRAM was 90.3 μg/mL, representing 12.54% of the RA
content of HRAM aqueous/ethanolic extract. This is in
reasonable agreement with in vivo post-hepatic RA, FA,
CA, CO and methyl-RA recoveries reported by others,
who report that 5.47% of total RA administered to rats
(50 mg/kg BW) is recovered in urine within 18 h after RA
administration, either as intact RA or its associated
metabolites [18]. This provides evidence that there is
considerable disappearance of dietary RA that is not
accounted within its known hepatic metabolites (FA, CO,
CA and methyl-RA). The relative amounts of RA, CA,
FA, and CO identified in urine of rats provided with
dietary RA are 1, 0.1, 0.2, and <0.01, respectively. This is
in reasonable agreement with the relative contributions
of these compounds in our biological extract of 1, 0.6,
0.06, and 0.09, respectively. The differences that are
observed between the profile of RA and its metabolites in
vivo and in our model may result from biotransformation
reactions and transporter mechanisms in the kidney;
reactions which occur in vivo but are not accounted for
within our model. Thus, while the biological extraction
procedure in the current study provides reasonable
approximation of post-hepatic RA metabolism with
respect to total RA and metabolite recoveries and com-
position, there may be benefit to further developing the
model to incorporate aspects of renal biotransformation
and transport. The fate of remaining 87.4% of RA added
to our biological extract is not known; there are a number
of peaks on the chromatograph that are, as yet, unidenti-
fied. These peaks will be identified as part of our ongoing
research.
We observed that CO, CA and FA were identified in the
aqueous extract of CM but not in HRAM, owing simply
to these compounds accumulating naturally in the variety
of mint which we used as our control and not in HRAM.
The fact that there was negligible change in these com-
pounds in CMsim may be due to differences in the initial
amount of RA which was available for metabolism. The
RA  c o n c e n t r a t i o n  o f  C M  w a s  m a r k e d l y  l o w e r  t h a n  i n
HRAM, and metabolites formed from the metabolism of
RA by microsomes in CMsim were added to a pre-existing
pool of CO, CA and FA. These initial parent phenolics
likely endured some level of degradation through the
digestion procedure, decreasing their initial concentra-
tions and resulting in a measurement of no net change.
While phytochemical profile of HRAMsim in the cur-
rent study correlates reasonably well with existing litera-
ture describing post-hepatic metabolites of RA in
rodents, pharmacokinetic (PK) analysis of oral HRAM is
necessary to confirm that our biological extraction proce-
dure accurately predicts in vivo biotransformation of
HRAM. As such, PK studies with HRAM are currently
underway in horses and in dogs in our laboratory. There
are a number of additional limitations to the current
method:
1. There may be species differences in metabolism of
secondary plant metabolites. For our experiments we
chose male rat microsomes because they were readily
available and well-characterized. However, effect of
microsomes may differ when they are sources from
human, equine or other species.
Figure 6 Interleukin-1β [IL-1] production by cartilage explants stimulated with LPS [3 or 0 μg/mL; Panels A and B, respectively]. Explants 
were conditioned with HRAMsim [0, 8, 40, or 80 μg/mL] for 96 h, and were stimulated with LPS for the final 48 h. Data shown are for the final 48 hours 
only.
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2. While we were able to identify hepatic metabolites
in our biological extract, we did not look for com-
pounds which might preclude a similarity with post-
hepatic metabolism, Future studies should incorpo-
rate such tests.
3. There are various in vivo mechanism such as red
c e l l  s e q u e s t e r i n g  o f  p o s t - h e p a t i c  p r o d u c t s  o r  c o m -
partmentalization of bioactive compounds in certain
tissues and/or organs which could make such com-
pounds unavailable for use in inflammatory situa-
tions. While it is not reported that such mechanisms
act upon RA in vivo, it is not known whether they
may be a factor in other, as yet unidentified com-
pounds within HRAM. Further studies must attempt
to further characterize HRAM with respect to phy-
tochemical profile and attempt to determine in vivo
storage and/or PK profiles.
The most notable effect of the biological extract of
HRAMsim in the current study was a dose-dependent and
marked inhibitory effect on LPS-induced PGE2 by carti-
lage explants. This was evident even at the lowest dose
tested (8 μg/mL), which is approximately equivalent to a
dose of 3.3 g for an average 78 kg person (assuming 100%
bioavailability of the active constituents). It is not unusual
for herbal plants to possess anti-inflammatory properties;
indeed, even aspirin has its historical roots in the bark of
the white willow tree. What is unique about HRAM,
however , is the low dose at which its striking effect on
LPS-induced PGE2 was observed. To our knowledge, this
magnitude of effect has not previously been reported for
herbs on cartilage tissue. M. spicata is a very robust crop
with a long growing season, and can be cultivated in
widely divergent agronomic zones making it a potentially
important and exciting commercial source for anti-
inflammatory products. How HRAMsim exerts its effect
on LPS-induced PGE2 production is not known, but our
study did not produce compelling evidence for an impor-
tant role of RA. We did not identify any significant bio-
logical effects of CM, the amount of which was scaled
upwards to contain equivalent amounts of RA as in
HRAM. Furthermore, neither RA nor three of its hepatic
metabolites (CO, CA and FA) demonstrated inhibitory
activity towards LPS-induced PGE2. Among several can-
didates for bioactive, methyl-RA may be a significant
contributor to the observed anti-inflammatory effect of
HRAMsim as it is a major hepatic metabolite of RA [18].
We did not test methyl-RA, owing to an inability to
obtain reliable standard; the literature does not yet
describe anti-inflammatory effects of methyl-RA, either
in cartilage or any other tissue, but this is a question that
begs investigation in future research.
Given the reported effect of RA [24] and Mentha sp. [9]
on IL-1 production, we hypothesized that an effect of
HRAMsim on PGE2 would be mediated, at least in part, by
a n  i n h i b i t o ry  e f f ect  o f  H RAM  u po n  LPS- i n d u c ed  IL - 1
production. Our data do not support this hypothesis.
This may again be a matter of dose, as the amount of RA
used in our experiment (0.64 μg/mL) was lower than that
reported bioactive by others (1.0 μg/mL) [24]. But it is
very interesting that, despite the low concentration of RA
in the lowest HRAM dose tested, we still saw marked
inhibition of LPS-induced PGE2 by HRAM.
The effect of HRAMsim on nitric oxide was expected,
given the previously demonstrated antioxidant properties
of HRAM [13] and Mentha spicata [25], as well as
reported inhibitory effects of Mentha sp. on nitric oxide
formation [26,27]. While a clear concentration-depen-
dency in the primary outcome variable (ie. PGE2) was
observed, all doses of HRAMsim performed the same with
respect to their ability to inhibit LPS-induced nitric
oxide, and indeed there appeared to be a reduction in
NO-inhibiting ability at the highest dose of HRAMsim.
This may simply reflect a circumstance where the maxi-
mum threshold of NO inhibition was reached, beyond
which exposure of explants to increasing concentrations
of HRAMsim did not achieve any change in response.
Another possible explanation is that HRAMsim  may
inhibit NO production through multiple biological path-
ways which are sensitive to HRAMsim inhibition at vary-
ing doses, which could also account for the absence of a
net dose-responsive relationship. Searching for answers
to this question may involve systematically blocking
known contributors to nitric oxide production and
observing the inhibitory effect of HRAMsim  on LPS-
induced NO production. It is noteworthy that, contrary
to reports that RA also inhibits NO formation [24], our
study did not find that RA was effective at reducing LPS-
induced nitric oxide. Nor were any of the RA metabolites
tested. Thus, we have not identified a causative phy-
tochemical of NO inhibition. The concentration of RA we
tested was approximately 64% of doses reported to pro-
duce antioxidant activities (1 μg/mL) [24], which may be
why we did not see a significant effect of RA on LPS-
induced NO. Also, the effect of simulated digestion fluid
on bioactivity of RA is not reported, and it is conceivable
that this may influence biological activity. Future research
should compare RA in simulated digest and RA in physi-
ological saline to determine the effects of vehicle on bio-
activity of RA. Assuming that RA (and its associated
metabolites) is not the primary bioactive phytochemical,
a good candidate for future investigation may be the fla-
vonoid fraction of HRAM. Flavonoids are stable phenolic
compounds found abundantly in plants including Mentha
spicata [25], and have reported modulatory effect on NO
formation [28] and NO scavenging [26,27]. While the sta-
bility of some flavonoids in the presence of intestinalPearson et al. BMC Complementary and Alternative Medicine 2010, 10:19
http://www.biomedcentral.com/1472-6882/10/19
Page 10 of 11
enzymes has been questioned [29], the flavonoid fraction
of HRAM is never-the-less a logical place to continue the
search for a primary bioactivity phytochemical in HRAM.
The effect of HRAM on GAG release is a novel finding,
and one which has not been previously reported for Men-
tha sp. The mechanism by which HRAMsim reduces GAG
release is not known, but may be a secondary effect of
reduced NO formation, as NO is shown to increases
post-translational aggrecan degradation under certain
circumstances [30]. Unlike the previous outcome mea-
sures discussed, inhibition of LPS-induced GAG release
by HRAMsim was not independent of RA. RA (0.64 μg/
mL) significantly inhibited GAG release at 24 h of LPS
exposure. However, peak LPS-induced GAG production
at 24 h in RA-conditioned explants (106.2 ± 10.4 μg/mL)
was still about 20% higher than peak LPS-induced GAG
release from explants conditioned with the lowest dose of
HRAM (82.9 ± 16.1 μg/mL), suggesting that other com-
pounds, or synergies between RA and its metabolites,
magnify the protective effect of RA on GAG loss. We did
not test the combined (synergistic) effect of RA and its
metabolites, and this should be tested in future research.
Furthermore, future research should evaluate the effects
of HRAM on factors associated with cartilage anabolism,
such as type II collagen and aggrecan in addition to activ-
ity and/or expression of enzymes which regulate homeo-
stasis of cartilage matrix.
We did not observe any effect of HRAM on the ratio of
live- and dead-cell staining, supporting the safety of this
material on chondrocyte viability at the doses tested. Via-
bility was affected, however, by the highest dose of CMsim;
thus provision of RA via HRAM appears to be a safer
vehicle for delivery of RA to cartilage tissue than CM,
presumably due to the inordinate up-scaling of other phy-
tochemicals present in CM.
Conclusions
It is concluded that simulated digestion in the presence of
liver microsomes is an effective means for producing a
biological extract of bioactive plant materials. HRAM is a
strong inhibitor of PGE2 and NO in LPS-stimulated carti-
lage explants, and is a weak inhibitor of GAG release. Fur-
ther research into the in vivo effects of this plant is
warranted.
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